Idexx Laboratories reports Q4 comparable EPS $2.07, consensus $1.94

Reports Q4 revenue $828.57M, consensus $820.91M. "As a result of outstanding execution by IDEXX commercial and operational teams, IDEXX delivered continued solid CAG Diagnostics recurring revenue growth across our major regions and record full-year premium instrument placements, with solid gains across our major in-clinic platforms," said Jay Mazelsky, president and CEO. "Veterinarians continue to look to IDEXX as their trusted partner to deliver highly effective diagnostic testing solutions and information management products to support growing demand for companion animal healthcare. We’re well positioned to build on our growth momentum moving forward as we address the significant untapped potential for companion animal healthcare globally."